Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
The immune checkpoint receptor LAG-3 suppresses Natural Killer cells against cancer.
EF 2018-19
Résumé
Our immune system is our body’s natural defence against cancer which includes our T cells and Natural Killer (NK) cells that function to destroy tumour cells. However, a common characteristic of cancer is the ability of tumour cells to avoid immune responses and develop in people even if they are not immunocompromised. Currently, research is being done to explain how tumour cells are able to avoid immune responses and to explore potential therapies which can increase the ability of T and NK cells to fight cancer.
When the immune checkpoint receptor LAG-3 found on T cells binds its target molecules found on tumor cells, the anti-cancer response of T cells is decreased. This decrease is so prominent that antibodies designed to block LAG-3 from interacting with its targets are currently being studied in clinical trials as a potential cancer treatment. LAG-3 is also known to be found on NK cells, but the function of LAG-3 on NK cells is currently unclear.
With our study, we hope to investigate two hypotheses. We hypothesize that the interaction between LAG-3 on NK cells with its target molecules on tumour cells decreases the ability of NK cells to fight cancer. Accordingly, we also hypothesize that the tumour-killing activity of NK cells can be enhanced by blocking this interaction, therefore presenting a possible method of cancer treatment. We believe that this project will shed light on the methods through which cancer can suppress our immune responses and generate knowledge that can be used to design new and more effective cancer therapies which harness the natural cancer fighting activity of our immune systems.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406408
Name
Chan Cynthia
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The immune checkpoint receptor LAG-3 suppresses Natural Killer cells against cancer.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Checkpoint Blockade; Immune Checkpoint Receptors; Immune Evasion; Immunotherapy; Lag-3; Nk Cells; Pd-1; Tumor Microenvironment
Abstract
Our immune system is our body’s natural defence against cancer which includes our T cells and Natural Killer (NK) cells that function to destroy tumour cells. However, a common characteristic of cancer is the ability of tumour cells to avoid immune responses and develop in people even if they are not immunocompromised. Currently, research is being done to explain how tumour cells are able to avoid immune responses and to explore potential therapies which can increase the ability of T and NK cells to fight cancer.
When the immune checkpoint receptor LAG-3 found on T cells binds its target molecules found on tumor cells, the anti-cancer response of T cells is decreased. This decrease is so prominent that antibodies designed to block LAG-3 from interacting with its targets are currently being studied in clinical trials as a potential cancer treatment. LAG-3 is also known to be found on NK cells, but the function of LAG-3 on NK cells is currently unclear.
With our study, we hope to investigate two hypotheses. We hypothesize that the interaction between LAG-3 on NK cells with its target molecules on tumour cells decreases the ability of NK cells to fight cancer. Accordingly, we also hypothesize that the tumour-killing activity of NK cells can be enhanced by blocking this interaction, therefore presenting a possible method of cancer treatment. We believe that this project will shed light on the methods through which cancer can suppress our immune responses and generate knowledge that can be used to design new and more effective cancer therapies which harness the natural cancer fighting activity of our immune systems.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chan, Cynthia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~